Total Funding
62
Total FundingSeries B raised
Growth Score
pts
Heat Score
-8 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
123183
Janpix operates as an oncology-focused startup.
Acquired by 
Centessa Pharmaceuticals
- Patrick T. Gunning: Chief Scientific OfficerPast Role: Dunad Therapeutics, Founder, Acting CEO & CSO
Roman Fleck: CEOPast Role: Boehringer Ingelheim, Team Member
About the Company
Janpix is discovering and developing inhibitors of Signal Transducer and Activator of Transcription (“STAT”) proteins. Most members of this family of transcription factors have been known for some time and their relevance in certain cancers, in particular for STAT3 & STAT5, validated. Inhibiting the function of STAT proteins though has been
very challenging thus far and Janpix developed new chemistry to address this complex problem.
